The nearly 30,000-patient trial showed the vaccine had 93% effectiveness against known variants. (Image source: Novavax)
The severe weather led to clinic closures, canceled appointments and shipment backlogs nationwide (Image source: CVS Health)
The company's COVID-19 vaccine candidate is still undergoing clinical trials.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
| Website: | www.novavax.com |
| Email: | ir@novavax.com |
| Main Phone: | +1 240 268-2000 |
| Address: | 21 Firstfield Road |
| Address 2: | Suite 1188, Bentall 5 |
| State: | MD |
| City / Town: | Gaithersburg |
| Country: | US |
| Postal Code: | 20878 |
| Exchange: | NGS |
| CEO: | Stanley Charles Erck |
| Employees: | 791 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
The nearly 30,000-patient trial showed the vaccine had 93% effectiveness against known variants. (Image source: Novavax)
The severe weather led to clinic closures, canceled appointments and shipment backlogs nationwide (Image source: CVS Health)
The company's COVID-19 vaccine candidate is still undergoing clinical trials.
The company had delayed the trial twice due to issues in scaling up the manufacturing process.
It's a major vote of confidence from the world's largest vaccine producer.
The study is expected to enroll up to 10,000 participants aged between 18 and 84. The candidate vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage trial.
The promise to play by established rules underlines a highly politicized debate over what action is needed to rein in COVID-19 quickly and to jumpstart global business and trade.
The award announced by the Department of Health and Human Services is the biggest yet from "Operation Warp Speed" to cover testing and manufacturing of a potential vaccine for the novel coronavirus.
The company expects to begin mid-stage trials in the US in mid-summer.
Under its existing BARDA contract, Emergent's new task order commits its manufacturing facilities to produce COVID-19 vaccine candidates through 2021.
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2021 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
